FF-10850, a Novel Liposomal Topotecan Achieves Superior Antitumor Activity via Macrophage- and Ammonia-Mediated Payload Release in the Tumor Microenvironment

Topotecan, an approved treatment for refractory or recurrent ovarian cancer, has clinical limitations such as rapid clearance and hematologic toxicity. To overcome these limitations and maximize clinical benefit, we designed FF-10850, a dihydrosphingomyelin-based liposomal topotecan. FF-10850 demons...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimoyama, Susumu, Okada, Ken, Kimura, Toshifumi, Morohashi, Yasushi, Nakayama, Shinji, Kemmochi, Sayaka, Makita-Suzuki, Keiko, Matulonis, Ursula A., Mori, Mikinaga
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Large Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690090/
https://www.ncbi.nlm.nih.gov/pubmed/37683276
http://dx.doi.org/10.1158/1535-7163.MCT-23-0099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690090/
https://www.ncbi.nlm.nih.gov/pubmed/37683276
http://dx.doi.org/10.1158/1535-7163.MCT-23-0099

Ejemplares similares